Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Sensitive and easy screening for circulating tumor cells by flow cytometry
Alexia Lopresti, … , Claire Acquaviva, Emilie Mamessier
Alexia Lopresti, … , Claire Acquaviva, Emilie Mamessier
Published June 13, 2019
Citation Information: JCI Insight. 2019;4(14):e128180. https://doi.org/10.1172/jci.insight.128180.
View: Text | PDF
Resource and Technical Advance Oncology

Sensitive and easy screening for circulating tumor cells by flow cytometry

  • Text
  • PDF
Abstract

Circulating tumor cells (CTCs) provide easy, repeatable, and representative access to information regarding solid tumors. However, their detection remains difficult because of their paucity, their short half-life, and the lack of reliable surface biomarkers. Flow cytometry (FC) is a fast, sensitive, and affordable technique, ideal for rare-cell detection. Adapted to CTC detection (i.e., extremely rare cells), most FC-based techniques require a time-consuming pre-enrichment step, followed by a 2-hour staining procedure, impeding the efficiency of CTC detection. We overcame these caveats and reduced the procedure to less than 1 hour, with minimal manipulation. First, cells were simultaneously fixed, permeabilized, and then stained. Second, using low-speed FC acquisition conditions and 2 discriminators (cell size and pan-cytokeratin expression), we suppressed the pre-enrichment step. Applied to blood from donors with or without known malignant diseases, this protocol ensures a high recovery of the cells of interest independently of their epithelial-mesenchymal plasticity and can predict which samples are derived from cancer donors. This proof-of-concept study lays the bases of a sensitive tool to detect CTCs from a small amount of blood upstream of in-depth analyses.

Authors

Alexia Lopresti, Fabrice Malergue, François Bertucci, Maria Lucia Liberatoscioli, Severine Garnier, Quentin DaCosta, Pascal Finetti, Marine Gilabert, Jean Luc Raoul, Daniel Birnbaum, Claire Acquaviva, Emilie Mamessier

×

Figure 1

Validation of the antibodies used in the study.

Options: View larger image (or click on image) Download as PowerPoint
Validation of the antibodies used in the study.
Each antibody was tested...
Each antibody was tested on positive and negative controls cells by microscopy (left panel) and flow cytometry (right panel), n = 3 times each. Only one representative example is shown. Left panel: validation by immunofluorescence. HCT 116 (epithelial malignant cell line), MDA-MB-231 (myoepithelial malignant cell line), and leukocytes (isolated from fresh blood with a density gradient) were used as positive and/or negative controls depending on the marker tested. Images on the left (A, D, G, and J) correspond to the positive staining of the antibody specified in each row, and images on the right (B, E, H, and K) correspond to the negative control. Scale bars: 10 μm. (C, F, I, and L) Validation by flow cytometry. HCT 116 or MDA-MB-231 cells were spiked in blood. Each antibody was used separately. Signal obtained in leukocytes is in light gray, in HCT 116 in dark gray, and in MDA-MB-231 in purple. Fluorescence quantification (staining index [SI]) of each marker was provided for each cell population. Pan-KRT, pan-cytokeratin.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts